StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research report report published on Saturday. The brokerage issued a sell rating on the medical technology company’s stock.
BIOL has been the subject of several other research reports. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd. Ascendiant Capital Markets lowered their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.
Get Our Latest Research Report on BIOL
BIOLASE Price Performance
BIOLASE (NASDAQ:BIOL – Get Free Report) last announced its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share for the quarter. The company had revenue of $11.56 million for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its holdings in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. Institutional investors own 8.79% of the company’s stock.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Articles
- Five stocks we like better than BIOLASE
- How to Invest in Blue Chip Stocks
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What Is WallStreetBets and What Stocks Are They Targeting?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Invest in the Best Canadian StocksĀ
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.